Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Pairnomix Announces Attendance At 2017 Fall Conferences



PLYMOUTH, Minn., Oct. 5, 2017 /PRNewswire/ -- Pairnomix, LLC, a personalized genetic evaluations company, today announced that it will have a presence at six upcoming medical and scientific conferences. The company will be presenting data from recent case studies that focus on epileptic encephalopathies. The conferences Pairnomix will attend include:

Pairnomix, LLC (PRNewsFoto/Pairnomix, LLC)

About Pairnomix 
Pairnomixtm, a personalized genetic evaluations company, is committed to helping people living with rare diseases understand the genetic cause of their condition and explore potential treatment options that are available today. Pairnomix's initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.

 

SOURCE Pairnomix, LLC


These press releases may also interest you

at 16:06
In the fast-moving 21st century with a 7-billion strong population ? accessing any consumer service requires identity information ? signing up on websites, e-commerce checkouts, accessing private properties, buying bitcoins, or getting loans....

at 14:45
Award winning interactive agency, Inhance Digital, breaks new technology boundaries in entertainment and immersive industries with the pioneering, multisensory VR experience HERO premiering at 2018 Sundance Film Festival in Park City, Utah from...

at 14:34
BlockMesh, a software company based in Mauritius ? utilizes the latest innovations in mesh networking technology, to create cost-free communication networks aiming to disrupt the global communications industry in 2018. Mesh technology is a...

at 12:12
Graft, the first global, open-sourced payment gateway blockchain network designed for Point-of-Sale, moving ahead of schedule and have launched its mainnet on January 16, 2018, before the start of the company's Initial Coin Offering (ICO), which...

at 10:05
Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab,...

at 08:15
Plasan North America, a Michigan-based manufacturer of military armored solutions technologies, is pleased to announce that Colonel John Cavedo, Jr. (RET), is joining our company as Vice President of Business Development and Program Management. ...




News published on 5 october 2017 at 09:00 and distributed by: